Hexarelin Acetate 5mg Review

Hexarelin acetate is one of the most potent synthetic growth hormone secretagogues (GHS) characterized in the peer-reviewed literature. First synthesized and described by researchers at Università degli Studi di Milano in the early 1990s, it has accumulated a respectable body of published data across rodent models, primate pharmacology studies, and a limited but informative set of human clinical investigations conducted under controlled research conditions. For laboratory researchers working on GH-axis biology, somatotroph signaling, cardiac metabolism, or body-composition modeling, hexarelin occupies a distinctive niche: it is more potent on a molar basis than GHRP-2 and GHRP-6 in head-to-head secretion assays, yet its clean hexapeptide structure makes it a tractable ligand for receptor-selectivity experiments.

This review covers the chemistry, receptor pharmacology, published efficacy data, pharmacokinetics, purity expectations, and research-context dosing information for the Apollo Peptide Sciences 5 mg vial currently listed at $35.00. All compound discussion is framed strictly within the context of laboratory research. No section of this article constitutes clinical advice, prescribing guidance, or encouragement to use any peptide in human subjects outside of formally approved clinical trials.

Editor's Verdict

Hexarelin stands out in the GH secretagogue class for three reasons: exceptional potency at the GHS-R1a receptor, well-documented cardiac and cytoprotective signaling independent of GH release, and a published pharmacokinetic profile detailed enough to design meaningful pre-clinical studies. The 5 mg vial from Apollo Peptide Sciences represents a practical entry-point quantity; 5 mg yields enough material for a well-powered small-animal study or an extended series of cell-culture experiments without the cost overhead of a 10 mg purchase when initial titration work is underway.

The evidence base is stronger than many peptides in this category. Deghenghi, Ghigo, Muccioli, Torsello, and Broglio are among the researchers who have contributed peer-reviewed data that a laboratory team can actually lean on when designing protocols. The cardiac biology data, including work from Locatelli and colleagues on ischemia-reperfusion models, adds a second mechanistic dimension that differentiates hexarelin from simpler secretagogues.

The main research limitation worth flagging: rapid tachyphylaxis (receptor desensitization) has been reliably observed in both rodent and human studies when hexarelin is administered repeatedly over days. Researchers designing sub-chronic or chronic exposure protocols should account for this in their statistical models and consider cross-reference with GHS-R1a internalization literature before finalizing dosing schedules.

Specifications

The lyophilized acetate salt form provides substantially better shelf stability than aqueous preparations. Hexarelin is susceptible to oxidative degradation at the tryptophan residues (specifically at position 2 which contains a synthetic D-2-methyltryptophan modification); proper cold-chain handling is not optional. See the reconstitution guide for detailed handling procedures.

What It Is, Chemistry, Origin, and Sequence Detail

Historical Context and Development

Hexarelin was synthesized as part of a systematic medicinal chemistry effort at Europeptides (Argenteuil, France) in collaboration with researchers at the University of Milan during the early 1990s. The project aimed to develop orally active or parenterally practical GH-releasing peptide (GHRP) analogs with improved potency over the parent compound GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2), which itself had been characterized in the Bowers laboratory at Tulane University. ^[1]

The key structural modification that defines hexarelin relative to GHRP-6 is the incorporation of D-2-methyltryptophan at position 2, replacing D-tryptophan. This single methyl substitution on the indole nitrogen profoundly increases receptor binding affinity and resistance to enzymatic degradation, translating to greater in-vivo potency per microgram administered. ^[2] The compound received the International Nonproprietary Name (INN) "examorelin" and the research designation EP 23905, though "hexarelin" remains the term used in the vast majority of the published literature.

Primary Sequence and Chemical Structure

The full sequence of hexarelin is: His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2 (C-terminal amide). The six-residue structure is compact and largely hydrophobic, contributing to its moderate lipophilicity and capacity to penetrate the blood-brain barrier in rodent studies, which has implications for both central GH-axis stimulation and direct hypothalamic effects. ^[3]

The D-amino acid configuration at positions 2 (D-2-methyltryptophan) and 5 (D-phenylalanine) renders those peptide bonds highly resistant to serine proteases, an important pharmacokinetic advantage over purely L-amino acid sequences. The C-terminal lysine amide contributes to positive charge at physiological pH, supporting electrostatic interaction with the extracellular loops of GHS-R1a. The molecular weight of the free base is 887.05 g/mol; the acetate salt adds approximately 60 g/mol depending on stoichiometry, placing the working molecular weight near 947 g/mol for molarity calculations. Researchers designing nanomolar to micromolar in-vitro incubation experiments should use the free-base molecular weight (887.05 g/mol) unless the vendor's certificate of analysis specifies acetate content and provides an adjusted MW.

Comparison to Related GHRPs

Within the GHRP structural class, hexarelin's D-2-methyltryptophan substitution places it structurally between GHRP-6 (parent compound), GHRP-2 (which incorporates D-alanine at position 6 and D-2-naphthylalanine at position 3), and ipamorelin (which uses aib-amino acids to reduce side-receptor activity). Hexarelin is generally acknowledged in receptor pharmacology literature as the most potent GHS-R1a agonist among commonly referenced peptide secretagogues, with EC50 values at GHS-R1a in the sub-nanomolar range in some competitive binding assays. ^[4]

Mechanism of Action

GHS-R1a Receptor Binding

Hexarelin's primary mechanism involves high-affinity agonism at the growth hormone secretagogue receptor type 1a (GHS-R1a), a seven-transmembrane G-protein-coupled receptor (GPCR) identified by Howard and colleagues in 1996 and subsequently deorphanized with the discovery of ghrelin as its endogenous ligand in 1999. ^[5] GHS-R1a is expressed most densely in the pituitary somatotroph cells and the hypothalamic arcuate nucleus, with lower-level expression in the hippocampus, ventral tegmental area, dorsal vagal complex, and peripheral tissues including heart, adipose tissue, and pancreatic islets. ^[6]

Hexarelin binds within the hydrophobic transmembrane bundle of GHS-R1a, engaging contact points at transmembrane domains 3, 5, 6, and 7 via its aromatic residues (tryptophan and phenylalanine) and electrostatic contacts at extracellular loop 2 via its N-terminal histidine. Binding affinity (Ki) values reported in radioligand displacement assays using [125I]-ghrelin or [125I]-hexarelin itself range from approximately 0.03 nM to 1.2 nM depending on species, tissue preparation, and assay conditions. The most commonly cited Ki in pituitary membrane preparations is in the range of 0.1-0.4 nM, consistent with sub-nanomolar functional potency. ^[4]

Downstream Signaling Cascades

GHS-R1a couples preferentially to Gq/11 proteins. Hexarelin-mediated receptor activation triggers phospholipase C-beta (PLC-beta), which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to generate inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 drives calcium release from the endoplasmic reticulum, and DAG activates protein kinase C (PKC). The resulting cytoplasmic calcium spike in somatotroph cells triggers exocytosis of pre-formed GH granules, producing the rapid (within minutes) GH pulse that is characteristic of GHS administration in vivo. ^[2]

Beyond the Gq/11 pathway, GHS-R1a signals through cAMP/PKA when stimulated by hexarelin in a manner that potentiates GHRH-mediated cAMP elevation, providing synergistic GH release when both signals are present simultaneously. This synergy is the mechanistic basis for the widely observed greater-than-additive GH secretory responses when hexarelin and GHRH are co-administered in animal research. ^[7] GHS-R1a also recruits beta-arrestin following hexarelin binding, initiating receptor internalization via clathrin-mediated endocytosis, which is the cellular mechanism underlying the tachyphylaxis observed with repeated dosing.

CD36 Scavenger Receptor Signaling

A defining feature that separates hexarelin from most other synthetic GHRPs is its documented activity at CD36, a class B scavenger receptor expressed on cardiomyocytes, macrophages, endothelial cells, and platelets. The hexarelin-CD36 interaction is GH-independent; it persists in hypophysectomized animal models and is unaffected by GH receptor antagonists. ^[8] This observation, published by Bodart and colleagues, was a pivotal finding that reframed hexarelin research: the compound is not simply a GH secretagogue but a ligand with direct peripheral receptor activity relevant to cardiac biology.

The CD36-mediated signaling initiated by hexarelin in cardiomyocyte models involves activation of the phosphatidylinositol 3-kinase (PI3K)/Akt survival pathway, reduction of reactive oxygen species generation, and suppression of mitochondrial permeability transition pore opening during simulated ischemia-reperfusion conditions. In rodent Langendorff heart preparations, hexarelin pre-treatment significantly reduced infarct size, an effect abolished by CD36 knockdown, confirming receptor specificity. ^[9] This cardioprotective biology has made hexarelin a useful probe compound in cardiac research independent of its role as a GH secretagogue.

Tissue Distribution of Relevant Receptors

GHS-R1a distribution across tissues determines which organ systems are biologically engaged when hexarelin reaches the systemic circulation. The hypothalamus and pituitary represent the primary axis for GH secretion. In the hippocampus, GHS-R1a activation by ghrelin and synthetic agonists including hexarelin has been linked to synaptic plasticity modulation and neuroprotective signaling via CREB phosphorylation and BDNF upregulation in rodent models. ^[6]

In adipose tissue, GHS-R1a signaling promotes lipolysis and modulates adipokine secretion, partly explaining the body-composition effects observed in animal studies with chronic hexarelin administration. In pancreatic beta cells, GHS-R1a activation has been associated with insulin secretion potentiation, a finding with metabolic research implications. CD36, the secondary target, shows high expression in the heart, liver, skeletal muscle, and monocyte-derived macrophages, giving hexarelin a broad peripheral tissue engagement profile that most synthetic GHRPs lack. ^[8]

What the Research Says

Study 1, Pituitary GH Secretion, Ghigo et al. (1994)

One of the earliest and most frequently cited human pharmacology studies on hexarelin was conducted by Ghigo and colleagues at the University of Turin. The investigators administered single intravenous bolus doses of hexarelin (0.2, 1.0, or 2.0 mcg/kg) or GHRH (1.0 mcg/kg) to healthy male volunteers and measured serum GH by radioimmunoassay at frequent intervals over 120 minutes. The primary endpoint was peak GH concentration and area under the curve (AUC) for GH release. ^[2]

Hexarelin at 2.0 mcg/kg produced mean peak GH concentrations of approximately 90 ng/mL, roughly six to eight times higher than the GHRH-alone response. Even the lowest hexarelin dose (0.2 mcg/kg) produced peak GH responses exceeding those of GHRH. The dose-response relationship was steep and nearly log-linear across the tested range. GH responses peaked at 20-30 minutes post-injection and returned to baseline within 90-120 minutes, consistent with the short half-life of hexarelin and rapid GHS-R1a desensitization.

A notable limitation of this study was its single-dose design; the tachyphylaxis question was not addressed. The all-male, healthy-volunteer cohort limits generalizability to aged, obese, or hyposomatotropic research models. Nevertheless, the magnitude of GH release and the dose-response data from this study have been referenced in nearly every subsequent hexarelin pharmacology paper as a benchmark for pituitary responsiveness, and the methodology has been replicated in modified form by multiple other groups. The key research implication is that hexarelin's efficacy at the pituitary is not incremental over other GHRPs; it is categorically higher, making it the preferred tool when maximal GH secretory drive is needed in an experimental design.

Study 2, Tachyphylaxis and Receptor Desensitization, Loche et al. (1997)

Loche and colleagues conducted a systematic investigation of hexarelin tachyphylaxis in a pediatric short-stature research cohort. Subjects received daily subcutaneous injections of hexarelin at a literature-reported research dose over a multi-week period; GH responses were measured by serial blood sampling after each injection. ^[10] The investigators documented a progressive attenuation of peak GH responses beginning within the first three to five days of daily administration, reaching approximately 40-60% reduction from the first-dose response by day 14.

Importantly, the tachyphylaxis was reversible; after a washout period of several weeks, first-dose GH responses were substantially restored. The study also measured IGF-1 and IGFBP-3 over the treatment period, finding modest but statistically significant elevations that were disproportionately small relative to the magnitude of GH pulses observed on day 1, suggesting that the biological downstream consequences of repeated hexarelin pulsing are buffered by the tachyphylaxis phenomenon itself.

From a research design perspective, this study is critical for any laboratory designing multi-day animal dosing protocols. The tachyphylaxis data suggests that pulsatile or intermittent dosing schedules (e.g., every 72 hours) may preserve GH secretory responses better than daily regimens. Researchers should build response-decay correction factors into statistical models when comparing early-treatment and late-treatment time points in sub-chronic studies. The underlying molecular mechanism, GHS-R1a internalization and downregulation, has been characterized in vitro using CHO cells stably expressing GHS-R1a, with recovery of surface receptor density correlating closely with the in-vivo washout timeline. ^[4]

Study 3, Cardiac Effects in Ischemia-Reperfusion, Locatelli et al. (1999)

Locatelli and collaborators published a landmark study examining hexarelin's effects in an isolated rat heart ischemia-reperfusion (I/R) model, using the Langendorff perfusion technique. ^[9] Hearts from adult male Wistar rats were perfused with hexarelin (1 nM to 100 nM) before, during, and after a standardized 30-minute global ischemia episode followed by 60-minute reperfusion. Endpoints included left ventricular developed pressure (LVDP) recovery, infarct size (triphenyltetrazolium staining), creatine kinase release as a myocardial injury marker, and apoptosis index by TUNEL staining.

Hexarelin-treated hearts demonstrated significantly better LVDP recovery (approximately 60-70% of pre-ischemia baseline versus 30-40% in vehicle controls), reduced infarct size, lower CK release, and reduced cardiomyocyte apoptosis. These protective effects were concentration-dependent across the 1-100 nM range and were not abolished by a GH receptor antagonist, confirming that GH itself was not the mediating factor given the ex-vivo, pituitary-absent preparation. The investigators subsequently demonstrated through CD36 antibody blockade experiments that the cardioprotective effect was substantially attenuated by CD36 neutralization, establishing the mechanistic link discussed in the mechanism section. ^[8]

The Langendorff model has known translational limitations: it does not recapitulate the neurohormonal and inflammatory milieu of in-vivo ischemia, and rat heart physiology differs substantially from human in terms of heart rate, metabolic substrate utilization, and mitochondrial dynamics. These caveats notwithstanding, the study remains foundational for any research group designing hexarelin-based cardiac protection experiments because it provides validated endpoints, dose ranges, and a mechanistic framework that has been reproduced by independent groups.

Study 4, Body Composition Effects in Aging Rats, Torsello et al. (2000)

Torsello and colleagues at the University of Milan conducted a controlled study in aged (24-month-old) male Sprague-Dawley rats, administering hexarelin via subcutaneous injection at literature-reported animal-equivalent doses over an eight-week period. ^[11] The primary outcome was body composition by dual-energy X-ray absorptiometry (DEXA), with secondary endpoints of plasma IGF-1, pituitary GH mRNA expression, tibial growth plate histomorphometry, and grip strength testing.

Hexarelin-treated aged animals showed significant reductions in fat mass (approximately 18% reduction from baseline versus 3% in controls) and preservation of lean mass relative to vehicle-treated age-matched controls. Plasma IGF-1 levels rose modestly but significantly, and GH mRNA in pituitary tissue was elevated in hexarelin-treated animals, suggesting stimulation of somatotroph gene expression in addition to secretagogue-mediated peptide release. Growth plate histomorphometry showed increased chondrocyte proliferative zone width in hexarelin-treated animals, consistent with IGF-1-mediated anabolic signaling.

An important caveat highlighted by the authors: fat mass reduction and lean mass preservation were partially confounded by differential food intake between groups, with hexarelin-treated animals consuming modestly less chow across the eight-week period. Given that hexarelin, like ghrelin, has orexigenic effects through GHS-R1a, this was somewhat paradoxical at first glance; the authors proposed that chronic IGF-1 elevation may have attenuated the appetite-stimulating effect of GHS-R1a signaling over the study duration. This finding has direct implications for researchers designing metabolic studies with hexarelin: food intake monitoring and pair-feeding controls should be included in study design.

Study 5, Hexarelin and Sleep Architecture, Frieboes et al. (1995)

Frieboes and colleagues, working in Munich, investigated the effects of hexarelin on sleep architecture and nocturnal GH secretion in healthy male subjects. Hexarelin or placebo was administered intravenously at sleep onset, and polysomnography with concurrent GH sampling was conducted across the entire sleep period. ^[12]

Hexarelin significantly increased slow-wave sleep (SWS) duration and the intensity of GH secretory bursts during early non-REM sleep compared to placebo. The SWS-promoting effect was partially independent of GH release, as it persisted (in attenuated form) even when GH responses were pharmacologically blunted in sensitivity analyses. The authors proposed a direct hypothalamic mechanism by which GHS-R1a activation modulates the GABAergic and somatostatinergic circuits governing sleep depth, consistent with subsequent work on central ghrelin receptor signaling in sleep regulation.

The study was limited by a small sample (n=8), the single-administration design, and the intravenous route, which has different kinetics than the subcutaneous route commonly used in animal research. Nonetheless, the data provide rationale for researchers investigating hexarelin in sleep or circadian biology models, particularly given the growing recognition of GHS-R1a as a circadian clock-modulating receptor.

Pharmacokinetics

Understanding the pharmacokinetic profile of hexarelin is essential for designing reproducible research protocols, selecting appropriate sampling time points, and interpreting biomarker data.

Half-Life Implications for Research Protocol Design

The approximately 30-minute plasma half-life in IV human pharmacology studies, and the comparable 20-35 minute half-life in rat subcutaneous studies, means that hexarelin's receptor occupancy is transient relative to many peptide agents. This has two practical research implications. First, GH sampling should occur within the 15-45 minute post-administration window to capture peak secretory responses; sampling beyond 90 minutes will miss the acute GH pulse in most experimental designs. Second, the short half-life combined with rapid GHS-R1a desensitization means that simple escalation designs (increasing dose on successive days to overcome tolerance) will encounter a ceiling imposed by receptor downregulation, not by insufficient drug concentration.

The moderate subcutaneous bioavailability (estimated 60-80% relative to IV) means that subcutaneous routes are feasible for rodent studies without requiring IV catheterization, a practical advantage for welfare-compliant experimental design. Intranasal administration has shown pharmacological activity in pilot human studies, though with attenuated GH responses relative to IV or subcutaneous routes, making it a less preferred route for mechanistic research requiring consistent exposure.

Blood-Brain Barrier Penetration

Hexarelin's moderate lipophilicity and D-amino acid content are proposed to facilitate passage across the blood-brain barrier, an observation supported by intracerebroventricular injection studies showing central GH-axis activation and by the sleep architecture effects described in the Frieboes study. ^{[3] [12]} This CNS accessibility distinguishes hexarelin from some larger peptides that are essentially excluded from the brain and is relevant for researchers studying central GH-axis regulation, sleep biology, or neuroprotective mechanisms. Precise brain penetration fractions have not been rigorously quantified in the published literature, representing a gap that future PK studies could address.

Purity and Verification

What a High-Quality CoA Should Contain

A certificate of analysis (CoA) for hexarelin acetate from a reputable supplier should document at minimum: HPLC purity (method, column type, solvent system, wavelength, and integration result), molecular weight confirmation by mass spectrometry (typically ESI-MS or MALDI-TOF), and appearance description. Premium vendors also provide amino acid composition analysis and sterility testing (USP chapter 71 or equivalent) for vials intended for in-vivo animal work.

For hexarelin specifically, the HPLC chromatogram should show a single dominant peak at the compound's characteristic retention time, with total impurity area less than 2% for a stated 98% purity product. The most common impurities in peptide manufacturing are deletion sequences (peptides missing one or more amino acid residues), oxidation products (particularly at tryptophan), and counterion impurities from incomplete salt exchange. A competent CoA will specify which peaks represent known vs. unknown impurities.

Mass spectrometry should confirm the monoisotopic or average molecular weight within ±0.1 Da of the theoretical value (887.05 g/mol free base, or the acetate salt value as specified). A vendor who provides only the molecular ion without isotope pattern data is offering less analytical rigor than one who provides full spectrum overlays.

Independent Verification Approaches

The most robust independent verification approach for a laboratory with analytical capacity is to submit a small aliquot (0.5-1 mg) to a third-party analytical laboratory for independent HPLC-UV and LC-MS/MS analysis before committing the full vial to a study. Services such as Janoshik Analytical (EU) and several CRO services in the US offer peptide purity testing for research-grade compounds at reasonable cost relative to the cost of a failed study.

Laboratories without in-house analytical capability should prioritize vendors who provide full CoA PDFs with batch-specific (not generic) data. A CoA that states "≥98% purity" without providing the actual chromatogram, the batch number, and the analysis date is not a document that supports rigorous research reproducibility. For in-vivo rodent studies, endotoxin testing (LAL assay, <1 EU/mg threshold typical for research grade) should be requested or conducted by the receiving laboratory to avoid inflammatory confounding in sensitive biological endpoints.

Dosage and Reconstitution

Reconstitution Fundamentals

Hexarelin acetate lyophilized powder reconstitutes readily in sterile water or 0.9% bacteriostatic saline. The compound is soluble at concentrations up to at least 1 mg/mL in aqueous buffers at physiological pH; higher concentrations (2-5 mg/mL) are achievable in acidified solutions (0.1% acetic acid in water) if needed for high-concentration stock preparation. For detailed reconstitution technique including aseptic procedure, needle sizes, and swirling vs. vortex guidance, see the reconstitution guide.

Worked Example 1, Preparing a 1 mg/mL Research Stock

Starting material: 5 mg hexarelin acetate lyophilized powder in a sealed vial. Add 5.0 mL of sterile bacteriostatic saline using a 25-gauge needle and 5 mL syringe. Allow the powder to dissolve by gentle swirling (avoid vortexing, which can introduce bubbles and shear peptide structure). Final concentration: 1 mg/mL (1000 mcg/mL). Aliquot into 0.5 mL portions (500 mcg each) in 1.5 mL cryogenic tubes; store at -20 °C and thaw one aliquot per experimental session.

Worked Example 2, Preparing a 0.1 mg/mL Working Solution for In-Vitro Cell Culture

From the 1 mg/mL stock: add 100 mcL of stock to 900 mcL of cell culture medium (serum-free, to avoid peptidase activity confounding results). Final concentration: 0.1 mg/mL (100 mcg/mL). Sterile-filter through a 0.22 mcm syringe filter into a pre-labeled, autoclaved 1.5 mL microcentrifuge tube. Use within 24 hours of preparation for cell-based assays; do not re-freeze diluted working solutions.

Worked Example 3, Calculating Animal-Equivalent Doses for a Rat Study

Published rat study dose: 80 mcg/kg SC (representative value from Torsello et al., body composition protocol). ^[11] Rat body weight: 350 g (0.350 kg). Required dose per rat: 0.350 kg x 80 mcg/kg = 28 mcg per injection. From 1 mg/mL stock: 28 mcg / 1000 mcg/mL = 0.028 mL (28 mcL) per rat. Using a 0.3 mL insulin syringe with 29-gauge needle, aspirate 28 mcL from the stock vial; administer via SC injection to the scruff region as per IACUC-approved protocol.

For detailed dosage calculation methodology, including body surface area scaling between rodent species and dose normalization approaches, see the dosage calculation guide.

Literature-Reported Research Dose Ranges

The following ranges are drawn directly from published pre-clinical and clinical research literature and are presented for researchers benchmarking their own experimental designs, not as guidance for human use.

• In-vitro cell-based assays (GH3 cells, primary pituitary cultures): 0.1 nM to 100 nM incubation concentration; EC50 values for GH release typically reported at 0.5-2 nM. ^[4]
• Rat in-vivo studies (SC injection): 40-160 mcg/kg body weight per session; acute GH secretion studies commonly use single-dose designs at this range. ^[11]
• Rat cardiac I/R studies (Langendorff perfusion): 1-100 nM in perfusion buffer; cardioprotective effects observed across this range. ^[9]
• Human clinical research (IV bolus, historical studies conducted under ethics approval): 0.2-2.0 mcg/kg, with 2.0 mcg/kg representing the approximate plateau for acute GH secretory response. ^[2]

Storage After Reconstitution

Reconstituted hexarelin solutions at 1 mg/mL are stable for approximately 28 days at 4 °C when prepared in bacteriostatic saline and stored in sealed, light-protected vials. Researchers conducting extended studies should aliquot the stock immediately upon reconstitution and freeze aliquots at -20 °C, thawing only what is needed for each experimental session. Repeated freeze-thaw cycles beyond three cycles are not recommended; peptide aggregation and oxidative degradation at the tryptophan residues increase with each thermal cycle.

Side Effects and Safety

Adverse Effects Observed in Published Research

The adverse effect profile of hexarelin as documented in historical clinical pharmacology studies (conducted under ethics approval before regulatory frameworks tightened around unapproved peptides) is relatively narrow but worth characterizing for researchers designing animal welfare monitoring protocols.

Cortisol and ACTH co-secretion: Unlike ipamorelin, which was specifically engineered for ACTH/cortisol selectivity, hexarelin reliably stimulates ACTH and cortisol release in addition to GH. Broglio and colleagues documented hexarelin-induced cortisol responses that, while smaller than GH responses in proportional terms, are statistically significant and dose-dependent. ^[13] In rat studies this translates to measurable adrenal weight changes with chronic hexarelin exposure, a confound that researchers measuring stress-sensitive endpoints (immune function, body composition, behavioral parameters) must account for.

Prolactin elevation: Hexarelin causes modest prolactin elevation via GHS-R1a activation on lactotroph cells, a class effect of most GHRPs. The prolactin response is smaller in magnitude than the GH response and generally transient, but researchers measuring reproductive or lactation endpoints should include prolactin time-series measurements in their sampling design.

Transient hypotension: At higher doses in animal studies, hexarelin has been associated with brief hypotensive episodes, proposed to involve CD36-mediated vasodilatory signaling in vascular endothelium. This has implications for animal welfare monitoring during acute high-dose IV experiments.

GHS-R1a desensitization and downstream endocrine axis suppression: Paradoxically, chronic hexarelin administration can suppress somatostatin neuron tone via feedback mechanisms, a finding documented by Deghenghi and colleagues in longer-term rat studies. ^[14] The net endocrine effect of chronic dosing schedules is therefore complex and not simply additive.

Tachyphylaxis: As discussed in the Loche study review above, rapid loss of GH secretory response with repeated administration is a consistent pharmacological property, not an idiosyncratic side effect. This is mechanistically driven by GHS-R1a internalization and should be considered a predictable feature of study design rather than an adverse event.

Absence of Genotoxicity or Organ Toxicity Data

Published genotoxicity, repeat-dose systemic toxicity (30-day, 90-day GLP studies), and carcinogenicity data for hexarelin are not available in the open literature. Researchers should not interpret the absence of toxicity findings as confirmation of safety; absence of data represents a knowledge gap, not a clean bill of health. Standard occupational safety precautions (gloves, eye protection, avoid aerosol generation) apply when handling lyophilized peptide powders.

How It Compares

Contextual Positioning Within the GH Secretagogue Class

Hexarelin is one of several synthetic peptide GH secretagogues available to the research community. Its unique combination of GHS-R1a potency and CD36 activity gives it a distinct profile, but it shares pharmacological territory with GHRP-2, GHRP-6, ipamorelin, and the non-peptide small molecule MK-0677 (ibutamoren). Understanding how these compare is essential for selecting the right probe compound for a given experimental question.

When to Choose Hexarelin Over Alternatives

Hexarelin is the preferred research tool when the experimental question requires maximal acute GH secretory drive, as it consistently outperforms GHRP-2, GHRP-6, and ipamorelin in direct comparison studies on this endpoint. ^[4] It is also the only peptide in this class with documented, mechanistically validated CD36 agonism, making it the sole appropriate choice for research questions involving hexarelin's direct cardiac or scavenger-receptor biology.

When selectivity for GH over cortisol/ACTH is the priority, ipamorelin is the more appropriate choice. When sustained GH elevation over hours to days is needed, MK-0677 or CJC-1295 combination protocols are better suited. When minimizing tachyphylaxis in multi-week protocols is paramount, ipamorelin or GHRH analogs again have advantages over hexarelin.

For researchers specifically studying GHS-R1a tachyphylaxis biology, hexarelin's rapid and pronounced receptor desensitization actually makes it the ideal tool, since the tachyphylaxis phenotype is reliably and quickly induced, providing a robust experimental model.

Open Research Questions

Despite hexarelin's relatively robust literature base compared to many research peptides, several mechanistically important questions remain unresolved or only partially addressed.

CD36 structural pharmacology: The precise binding mode and contact residues for hexarelin at CD36 have not been determined by crystallography or cryo-EM. Whether the hexarelin-CD36 interaction involves the same CD36 domain as fatty acid or thrombospondin binding is unknown, which limits rational design of CD36-selective hexarelin analogs for research use. This represents an opportunity for structural biology collaboration.

Neurological and sleep biology: The sleep-promoting effect of hexarelin documented by Frieboes and colleagues has not been reproduced in adequately powered rodent studies using standardized EEG-based sleep staging. The relative contributions of central GHS-R1a activation versus GH-mediated indirect effects on sleep architecture remain incompletely separated. ^[12]

Interaction with the ghrelin acylation system: Endogenous ghrelin requires octanoylation at Ser3 for full GHS-R1a activation; synthetic GHRPs including hexarelin bypass this requirement. Whether hexarelin and acylated ghrelin show true competitive binding kinetics at GHS-R1a, or engage the receptor in subtly different conformations with different signaling bias, has not been rigorously characterized with beta-arrestin recruitment assays using current biased agonism methodology. ^[5]

Chronic cardiac remodeling: The acute I/R cardioprotection data are compelling, but whether repeated hexarelin administration in intact animals produces durable cardiac structural or functional benefits (rather than just acute ischemia tolerance) is not addressed by available literature. Long-term cardiac remodeling studies with echocardiographic endpoints in relevant disease models (diabetic cardiomyopathy, pressure overload hypertrophy) would substantially advance the field.

Sex differences: The majority of published hexarelin studies used male subjects or male animals. The contribution of sex hormone milieu to GHS-R1a signaling efficiency and to CD36 expression levels in cardiac tissue is not well characterized for hexarelin specifically, though general GPCR sex-difference biology suggests these effects could be substantial.

Pharmacological Context and Adaptation Biology

GH Axis Physiology as Research Framework

The GH axis functions as an integrative neuroendocrine system responsive to nutritional state, sleep, stress, age, and sex steroid milieu. GH is secreted in pulsatile bursts, primarily during slow-wave sleep, with the pulse amplitude declining markedly with aging. ^[15] Hexarelin's pharmacological utility as a research tool derives partly from its capacity to interrogate this axis under controlled conditions: as an exogenous probe, it can reveal pituitary reserve, somatostatin tone, and GHRH responsiveness depending on experimental design.

The concept of somatotropic axis plasticity, the capacity of the GH-IGF-1 axis to reset its secretory patterns in response to chronic stimulation or inhibition, is directly relevant to hexarelin research. The tachyphylaxis data discussed above represents one facet of this plasticity. Equally important is the observation that in chronic sub-caloric conditions, GHS-R1a upregulation in the hypothalamus and pituitary can sensitize animals to hexarelin stimulation beyond baseline, a potential confound in nutritional stress models. Researchers should characterize baseline somatotropic axis status before interpreting hexarelin response data in metabolically perturbed animals. ^[6]

Ghrelin Receptor Biology in the Context of Aging Research

Aging is associated with a progressive decline in somatotropic axis activity, reduced pituitary GH secretory responsiveness, and falling IGF-1 concentrations. Hexarelin has been specifically studied as a pharmacological probe of the aging somatotropic axis in rodent models, with the Torsello et al. aged rat study being the most directly relevant example. ^[11] The aging-associated changes in GHS-R1a expression density and signaling efficiency are not fully catalogued, but available data suggest that aged animals show attenuated GH responses to hexarelin relative to young animals, consistent with receptor downregulation or altered coupling efficiency.

This age-related pharmacological shift is an important consideration for researchers designing longevity or healthspan studies using hexarelin. Dose-response characterization in the specific aged animal model planned is more informative than extrapolating from young-animal data, particularly for endpoint selection and statistical power calculations.

IGF-1 as Secondary Effector

The majority of hexarelin's anabolic, metabolic, and possibly neuroprotective effects are mediated not by GH directly but by IGF-1, which is produced primarily in the liver in response to circulating GH and locally in multiple tissues. IGF-1 binds the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase, triggering PI3K/Akt/mTOR and Ras/ERK/MAPK pathways that drive protein synthesis, cell survival, and proliferation. ^[15] Researchers measuring body-composition or anabolic endpoints in hexarelin studies should include both plasma IGF-1 and tissue-level IGF-1 mRNA as outcome measures, as liver-derived circulating IGF-1 and autocrine/paracrine muscle or bone IGF-1 can be differentially regulated.

The IGF-1-binding protein (IGFBP) system further modulates bioavailable IGF-1; IGFBP-3 is the primary carrier, and its levels track with GH stimulation. Including IGFBP-3 measurements provides a more complete picture of the net biological activity of the IGF-1 axis in hexarelin intervention studies.

Where to Buy

Apollo Peptide Sciences offers the 5 mg hexarelin acetate vial reviewed in this article. You can review the full product listing, batch-specific CoA information, and vendor quality documentation at our Hexarelin Acetate 5mg product page.

For researchers evaluating multiple suppliers or seeking guidance on what quality benchmarks to prioritize when selecting research peptide vendors, our supplier comparison guide covers CoA standards, third-party testing practices, and red flags to avoid.

Apollo Peptide Sciences states ≥98% purity by HPLC for this compound. Researchers who require independent verification before in-vivo work are encouraged to request the batch-specific CoA and compare it against the criteria described in the Purity and Verification section of this review.

At $35.00 for 5 mg, the price per milligram ($7.00/mg) is competitive within the current research peptide market for hexarelin acetate of this stated purity. Researchers planning larger studies requiring multiple vials should factor in the 5 mg vial yield: at an 80 mcg/kg dose in a 350 g rat, each vial supports approximately 178 individual injections, making a single 5 mg vial sufficient for a well-powered rat study without mid-study lot changes (which introduce potential batch-to-batch variability as a confound).